MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.98M | 31.85M | 30.88M | 30.60M | 28.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.98M | 31.85M | 30.88M | 30.60M | 28.71M |
| Cost of Revenue | 22.99M | 21.38M | 20.23M | 20.69M | 18.16M |
| Gross Profit | 9.98M | 10.47M | 10.65M | 9.90M | 10.55M |
| SG&A Expenses | 14.81M | 15.54M | 14.70M | 16.18M | 15.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -125.60K | -97.10K | -16.60K | -38.90K | 92.20K |
| Total Operating Expenses | 37.84M | 37.05M | 35.13M | 37.05M | 33.97M |
| Operating Income | -4.86M | -5.20M | -4.25M | -6.45M | -5.26M |
| Income Before Tax | -5.78M | -6.26M | -5.42M | -7.83M | -8.85M |
| Income Tax Expenses | -- | -- | -- | -- | -200.70K |
| Earnings from Continuing Operations | -5.78 | -6.26 | -5.42 | -7.83 | -8.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.78M | -6.26M | -5.42M | -7.83M | -8.65M |
| EBIT | -4.86M | -5.20M | -4.25M | -6.45M | -5.26M |
| EBITDA | -3.59M | -3.85M | -2.66M | -4.56M | -3.32M |
| EPS Basic | -0.01 | -0.02 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.66B | 1.65B | 1.64B | 1.63B | 1.60B |
| Average Diluted Shares Outstanding | 1.66B | 1.65B | 1.64B | 1.63B | 1.60B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |